Physician profile
Stephen M Ford
NPI 1649739715
$1,177.74
in general payments reported to CMS, 2019-2025
24 companies · $897 in 2025
The $897 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $280 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,177.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $181.57 | 2024-2025 | Omnipod, Omnipod |
| Chiesi USA, INC. | $130.44 | 2024 | Myalept |
| Tg Therapeutics, INC. | $93.32 | 2025 | |
| Novo Nordisk INC | $85.12 | 2024-2025 | Rybelsus, Ozempic |
| Dexcom, INC. | $71.68 | 2025 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $67.17 | 2025 | Ocrevus Zunovo |
| Ascendis Pharma Endocrinology INC | $63.62 | 2025 | Yorvipath |
| Xeris Pharmaceuticals, INC. | $61.36 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $58.94 | 2025 | Uplizna, Tepezza |
| Lundbeck LLC | $44.79 | 2025 | Vyepti |
| Vanda Pharmaceuticals INC. | $38.85 | 2025 | Ponvory |
| Corcept Therapeutics | $38.71 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $35.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $27.68 | 2025 | Ultomiris |
| Merz Pharmaceuticals, LLC | $23.03 | 2025 | Ampyra, Inbrija, Xeomin |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $22.15 | 2025 | Purified Cortrophin Gel |
| Boston Scientific Corporation | $20.69 | 2025 | Watchman Flx |
| Kyowa Kirin, INC. | $20.61 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $19.95 | 2025 | Imcivree |
| Neurocrine Biosciences, INC. | $18.61 | 2025 | |
| Emd Serono, INC. | $16.99 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.86 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $13.16 | 2024 | Alunbrig |
| Cequr Corporation | $7.44 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.